To Compare the Analgesic Effects of Different Nerve Block Analgesia Methods in Thoracoscopic Surgery

November 28, 2024 updated by: The First Hospital of Qinhuangdao

Comparison of Analgesic Effects of Ultrasound-guided Thoracic Paravertebral Block, Erector Spinae Muscle Block, Thoracic Paravertebral Block Combined with Erector Spinae Muscle Block, and Intercostal Nerve Block in Thoracoscopic Surgery

Comparison of analgesic effects of ultrasound-guided thoracic paravertebral block, erector spinae muscle block, thoracic paravertebral block combined with erector spinae muscle block, and intercostal nerve block in thoracoscopic surgery

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

120 patients undergoing elective thoracoscopic surgery were randomly divided into ESPB group (E group, n=30), TPVB group (T group, n=30), ESPB combine with TPVB group (ET group, n=30), ICNB group (I group, n=30). Patients in ESPB group underwent erector spinal block under ultrasound after anesthesia induction; Patients in TPVB group received thoracic paravertebral nerve block after anesthesia induction; Patients in ESPB group combined with TPVB group received thoracic paravertebral nerve block combined with erectoralis muscle block after anesthesia induction; Patients in INB group received intraoperative intercostal nerve block by the operator. All groups of patients received postoperative controlled intravenous analgesia (PCIA). Visual analogue scale (VAS) was used to evaluate the degree of pain 1h (T1), 24h (T2) and 48h (T3) after surgery. The mean arterial pressure (MAP), heart rate at T1-T3 were recorded, as well as the number of effective analgesic pump compression, the amount of sufentanil and the number of relief analgesia within 48h after surgery. The occurrence of postoperative adverse reactions such as nausea, vomiting, dizziness, retention time of thoracic drainage tube, postoperative hospital stay and postoperative pulmonary complications (pneumonia, atelectasis, pleural effusion, respiratory failure, etc.) were recorded.

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Hebei
      • Qinhuangdao, Hebei, China, 066000
        • Recruiting
        • First Hospital of Qinhuangdao
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • (1) American Society of Anesthesiologists (ASA) Grade I-II; (2) Age: 18-70 years old (3) double-hole thoracic surgery was performed; (4) Agree to participate in this study and sign the informed consent.

Exclusion Criteria:

  • (1) People who are allergic to anesthetics used in this study; (2) Patients with coagulation disorders (3) patients with severe heart disease, liver or renal insufficiency; (4) have a history of chronic pain or chronic opioid users (5) have a co-existing mental illness and are not fully capable of cooperating

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TPVB group
Ultrasound-guided thoracic paravertebral nerve block was used for postoperative analgesia after thoracic surgery
Other: TPVB group
Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB Group received thoracic paravertebral nerve block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
Experimental: ESPB group
Ultrasound-guided erector spinae muscle block was used for postoperative analgesia after thoracic surgery
Other: ESPB group
Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ESPB Group received erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
Experimental: TPVB combined ESPB group
Ultrasound-guided thoracic paravertebral nerve block combined with erector spinae muscle block was used for postoperative analgesia after thoracic surgery
Other: TPVB combined ESPB group
Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB combined ESPB group received thoracic paravertebral block combined with erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
Experimental: ICNB group
Intercostal nerve block was used for postoperative analgesia after thoracic surgery
Other: ICNB group
Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ICNB Group received intercostal nerve block for postoperative analgesia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative pain score
Time Frame: 48 hours after surgery
Visual analogue scale (VAS) was used to evaluate the degree of pain 1h (T1), 24h (T2) and 48h (T3) after surgery, the number of effective analgesic pump compressions and the number of remedial analgesia within 48h after surgery.
48 hours after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of postoperative complications
Time Frame: 48 hours after surgery
Mean arterial pressure (MAP), heart rate, postoperative nausea, vomiting, dizziness and other adverse reactions at T1-T3, retention time of thoracic drainage tube, and postoperative pulmonary complications (pneumonia, atractasis, pleural effusion, respiratory failure, etc.)
48 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The First Hospital of Qinhuangdao

Investigators

  • Study Director: Zhuo Liu, The First hosptial of Qinhuangdao

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 15, 2024

Primary Completion (Estimated)

November 20, 2024

Study Completion (Estimated)

January 20, 2025

Study Registration Dates

First Submitted

September 12, 2024

First Submitted That Met QC Criteria

September 12, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Estimated)

December 2, 2024

Last Update Submitted That Met QC Criteria

November 28, 2024

Last Verified

August 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • liuzhuo

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Analgesia

Clinical Trials on TPVB group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe